Navigation Links
Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
Date:5/20/2011

ty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care provide
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Lpath, Inc. (NASDAQ: LPTN ... reported interim results in a Phase 2a single-arm, ... a treatment for metastatic renal cell carcinoma (RCC) ... therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib ... (e.g., Afinitor®/everolimus), with a maximum of three failed ...
(Date:7/24/2014)... 2014  Market Diagnostics International LLC ("MDxI") today ... , a data resource that sets a new ... and identifying target In Vitro Diagnostics (IVD) customers. ... provides IVD manufacturers with accurate and comprehensive information ... and consistent definitions of laboratory categories and institutional ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today a co-promotion agreement with Illumina to facilitate ... sequence data for precision medicine and clinical trials. ... companies, through Illumina,s sales force, a solution including ... for data analytics and storage, and Cypher Genomics, ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:7/24/2014)... Mass. (PRWEB) July 24, 2014 Dr. ... Beth Israel Deaconess Medical Center in Boston, is the ... . Dr. Oettgen brings his considerable experience in the ... EBSCO Health . , Dr. Oettgen received his ... Medicine and completed his residency at Tufts New England ...
(Date:7/24/2014)... July 24, 2014 The first-ever successful ... a patient’s blood has been achieved by NFCR-supported scientist ... General Hospital. This is an important milestone on the ... selecting the best treatment for each patient. , ... “They often acquire new genetic features that make them ...
(Date:7/24/2014)... LSE Health and the European Heart Academy (EHA) ... pleased to announce the launch of a new, ... field of cardiovascular sciences. , The MSc in ... aims to equip cardiovascular specialists with the health ... take on advisory, management or leadership roles within ...
(Date:7/24/2014)... Texas at Arlington professor who co-authored a book ... in community revitalization has been awarded the Community ... Martinez-Cosio, associate professor in the School of Urban ... week at the society,s national conference, along with ... academic coordinator in the Urban Studies and Planning ...
(Date:7/24/2014)... seldom sufficient to read the declaration of contents if you ... fact, to do this you need to be a highly ... you can look directly into the molecular structure of the ... Engineering, is almost both, as he has developed a method ... biological samples. , The ,Fingerprints, of a Substance ...
Breaking Medicine News(10 mins):Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 3Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:LSE and ESC announce the launch of a new executive-style MSc 2Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3
... of Emerging Models of Care , , ... The Case Management Society of America ( CMSA ) will host ... the Grand Hyatt San Antonio in San Antonio, Texas . ... Association of Social Workers, DMAA: The Care Continuum Alliance, and The ...
... retail opportunities for fresh roasted fortified coffee. , ... ... first in caffeine and fat burning fresh roasted coffee products, has ... partnership in the coffee industry will push the JavaFit brand ...
... Individuals reporting a history of periodontal disease were ... a risk factor for heart disease, compared to ... according to an American Journal of Cardiology ... from Columbia University Medical Center and NewYork-Presbyterian Hospital, ...
... L. Chao today announced the appointment of five members to ... (NACOSH). The committee, established under the Occupational Safety and ... health and human services on occupational safety and health programs. ... the advisory committee members, willingness to contribute their time and ...
... The Lose For Good(TM) Campaign Reaches $1 Million Dollar Donation ... Banks in Need , , ... WTW ) is pleased to announce the donation of one ... Strength and Action Against Hunger. The donation was made ...
... Inc. (Nasdaq: ALXN ) today announced that Dr. ... at the 20th Annual Piper Jaffray Health Care Conference in ... 2, 2008. , , An ... You can access the webcast at: www.alexionpharm.com . An ...
Cached Medicine News:Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 2Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 3Health News:JavaFit, Distributors of Vitamin Infused Fresh Roasted Coffee, Announces Partnership With CLR Roasters 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 3Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: